Acam2000 Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Acam2000 market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by increased participation in clinical trials, a rise in smallpox cases, a growing demand for robust varicella vaccination, a surge in vaccine research funding, and increased healthcare expenditure.

In the forecast period, growth is expected to be fueled by the rising demand for coronavirus vaccines, increasing vaccination rates, improved immunization efforts, expanding public health preparedness initiatives, and a growing aging population. Key trends anticipated during this period include advancements in cell culture technology, innovations in vaccine development, improvements in cold chain logistics, the integration of AI and machine learning, and continued product innovation.

The rise in smallpox cases is expected to drive the growth of the acam2000 market in the future. Smallpox, a highly contagious and fatal disease caused by the variola virus, has seen increased cases due to factors such as failures in vaccination efforts, the deliberate release of the virus (bioterrorism), laboratory accidents, or the spread of the virus through global travel. ACAM2000 is a valuable vaccine that protects against smallpox by boosting the immune system to combat the virus and prevent infection. For example, according to a report from the Department of Health, a US-based organization, in August 2022, smallpox cases in the United States peaked, surpassing 30,000 cases for the year. Consequently, the rise in smallpox cases is fueling the growth of the acam2000 market.

Rising healthcare expenditure is expected to propel the growth of the acam2000 market. Healthcare expenditure refers to the total spending on healthcare services, including personal healthcare, preventive measures, and public health initiatives to improve health outcomes. This expenditure is increasing due to an aging population, the rise of chronic diseases, advancements in medical technology, high drug costs, inefficient payment models, and greater demand for healthcare services. A portion of this expenditure is directed toward ACAM2000 for vaccine procurement, stockpiling, distribution, and administration as part of biodefense and public health preparedness efforts. For instance, according to a report by the Office for National Statistics in May 2024, healthcare spending in the UK rose by 5.6% in nominal terms from 2022 to 2023, compared to a 0.9% increase in 2022. Additionally, long-term health and social care spending saw a real-term increase of 2.8% in 2022. Therefore, the growing healthcare expenditure is driving the expansion of the acam2000 market.

A key trend in the acam2000 market is the strategic focus on expanding vaccine indications to address emerging public health threats, such as mpox. Companies are seeking regulatory approvals to extend their vaccines’ use for high-risk populations. For example, in August 2024, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for the supplemental Biologics License Application (sBLA) for ACAM2000. This approval expands its indication to include the prevention of pox in individuals at high risk of infection. The approval is supported by prior human safety data and evidence from a controlled animal study showing the vaccine’s effectiveness against mpox virus exposure.

The key company operating in the acam2000 market is Emergent BioSolutions Inc.

North America was the largest region in the acam2000 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acam2000 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acam2000 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

ACAM2000 is a live vaccinia virus vaccine approved by the Food and Drug Administration (FDA) for immunization against smallpox. It is primarily administered to individuals at high risk of exposure, including military personnel and laboratory workers handling orthopoxviruses. ACAM2000 works by introducing a weakened virus related to smallpox, enabling the body to develop immunity against the disease.

The primary indications for acam2000 are smallpox and mpox. Smallpox, a viral disease caused by the variola virus, was eradicated globally through vaccination programs but remains a bioterrorism concern. Vaccines such as ACAM2000 are utilized to immunize high-risk individuals, ensuring preparedness for potential outbreaks. The vaccine is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and it is primarily used by adults and the geriatric population.

The acam2000 market research report is one of a series of new reports that provides acam2000 market statistics, including the acam2000 industry's global market size, regional shares, competitors with an acam2000 market share, detailed acam2000 market segments, market trends and opportunities, and any further data you may need to thrive in the acam2000 industry. This acam2000 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acam2000 market consists of sales of diluent for reconstitution, bifurcated needles, sterile syringes, and emergency use authorization documentation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.